Aatke van der Maas

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten et al. · BMJ · 2015 · 178 citations · Full text

Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study

Aatke van der Maas, Elisabeth Lie, Robin Christensen et al. · Annals of the Rheumatic Diseases · 2012 · 126 citations

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

Aatke van der Maas, Wietske Kievit, Bart J. F. van den Bemt et al. · Annals of the Rheumatic Diseases · 2012 · 99 citations

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit, Noortje van Herwaarden, F.H.J. van den Hoogen et al. · Annals of the Rheumatic Diseases · 2016 · 49 citations

Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial

Diane Marsman, Nathan den Broeder, F.H.J. van den Hoogen et al. · The Lancet Rheumatology · 2021 · 49 citations

Rheumatoid Disorder, Rheumatology, Proof-of-concept Trial +11